Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy

被引:13
作者
Gregorakis, AK
Malovrouvas, D
Stefanakis, S
Petraki, K
Scorilas, A [1 ]
机构
[1] Univ Athens, Fac Biol, Dept Biochem & Mol Biol, Athens 15701, Greece
[2] Univ Athens, Attikon Gen Hosp, Dept Urol, Athens, Greece
[3] Evangelismos Gen Hosp, Dept Urol, Athens, Greece
[4] Evangelismos Gen Hosp, Dept Pathol, Athens, Greece
关键词
tumor biomarkers; kallikreins; prostate; prostate cancer; PSA; free PSA; prostate specific antigen; serine proteases;
D O I
10.1016/j.cccn.2005.03.027
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: In this paper we study the Free/Total PSA kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy. Methods: Serum PSA, Free PSA and Free/Total Ratio were determined preoperatively, at the time of prostate removal (0 time) and then at 3, 6, 12, 24, 48, 72 and 168 h, from 9 patients with clinically localized prostate cancer who underwent radical retropubic prostatectomy. The elimination rates and half-lives of Total, Free PSA and F/T Ratio were studied applying one and two compartment models for pharmacokinetic analysis. Results: Surgical manipulations of the prostate caused a mean 2.16-fold increase. of PSA, 12-fold increase of free PSA and 4.2-fold increase of F/T PSA ratio. Removal of the prostate caused a rapid biphasic, biexponential elimination of Free PSA with a mean half-life of 0.8 h for the alpha (a) phase and 32.6 h for the beta (b) phase. PSA was eliminated following a rapid exponential (a) phase with a half-life of 1.15 h and a non-exponential (b) phase with a half-life of 71.96 h. Free/Total PSA followed a biphasic kinetic, with an initial exponential elimination phase and a mean half-life of 2.6 h and a second non-exponential increase phase with a doubling time of 130.8 h. Free/Total PSA reached its nadir very soon, at the first postoperative 24 h. Conclusions: Free/Total PSA kinetic after radical prostatectomy reflects the differences of Free and Total PSA elimination kinetics. Free/Total Ratio follows a biphasic kinetic, with an initial rapid exponential elimination phase, which is affected mainly by the rapid exponential (a) phase of Free PSA elimination and a second slow increase, which is affected mainly by the terminal non-exponential (b) phase of PSA elimination. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:196 / 201
页数:6
相关论文
共 28 条
[1]   PROSTATE SPECIFIC ANTIGEN DENSITY - A MEANS OF DISTINGUISHING BENIGN PROSTATIC HYPERTROPHY AND PROSTATE-CANCER [J].
BENSON, MC ;
WHANG, IS ;
PANTUCK, A ;
RING, K ;
KAPLAN, SA ;
OLSSON, CA ;
COONER, WH .
JOURNAL OF UROLOGY, 1992, 147 (03) :815-816
[2]   Clearance mechanism of prostate specific antigen and its complexes with α2-macroglobulin and α1-antichymotrypsin [J].
Birkenmeier, G ;
Struck, F ;
Gebhardt, R .
JOURNAL OF UROLOGY, 1999, 162 (03) :897-901
[3]   Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha1-antichymotrypsin from serum [J].
Björk, T ;
Ljungberg, B ;
Piironen, T ;
Abrahamsson, PA ;
Pettersson, K ;
Cockett, ATK ;
Lilja, H .
UROLOGY, 1998, 51 (01) :57-62
[4]   ALPHA(1)-ANTICHYMOTRYPSIN PRODUCTION IN PSA-PRODUCING CELLS IS COMMON IN PROSTATE-CANCER BUT RARE IN BENIGN PROSTATIC HYPERPLASIA [J].
BJORK, T ;
BJARTELL, A ;
ABRAHAMSSON, PA ;
HULKKO, S ;
DISANTAGNESE, A ;
LILJA, H .
UROLOGY, 1994, 43 (04) :427-434
[5]   Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy -: A critical assessment [J].
Brändle, E ;
Hautmann, O ;
Bachem, M ;
Kleinschmidt, K ;
Gottfried, HW ;
Grünert, A ;
Hautmann, RE .
UROLOGY, 1999, 53 (04) :722-730
[6]   LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE [J].
CARTER, HB ;
PEARSON, JD ;
METTER, J ;
BRANT, LJ ;
CHAN, DW ;
ANDRES, R ;
FOZARD, JL ;
WALSH, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16) :2215-2220
[7]  
Catalona WJ, 1996, PROSTATE, P64
[8]  
Lein M, 1997, EUR J CLIN CHEM CLIN, V35, P591
[9]  
LILJA H, 1991, CLIN CHEM, V37, P1618
[10]   Serum percent free prostate-specific antigen in metastatic prostate cancer [J].
Lin, DW ;
Noteboom, JL ;
Blumenstein, BA ;
Ellis, WJ ;
Lange, PH ;
Vessella, RL .
UROLOGY, 1998, 52 (03) :366-371